The very long-term prognosis and complications of lupus nephritis and its treatment

Citation
L. Bono et al., The very long-term prognosis and complications of lupus nephritis and its treatment, QJM-MON J A, 92(4), 1999, pp. 211-218
Citations number
19
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS
ISSN journal
14602725 → ACNP
Volume
92
Issue
4
Year of publication
1999
Pages
211 - 218
Database
ISI
SICI code
1460-2725(199904)92:4<211:TVLPAC>2.0.ZU;2-F
Abstract
Although the short- and medium-term (5-10 years) outcome of patients with l upus nephritis has been studied extensively, there are very few data on the second and subsequent decades. We studied outcome in 110 local patients in vestigated at a single centre before 1986, who all had potential follow-up of more than 10 years (actual 2-31 years, median 15.5 years). At last follo w-up, 40 patients were dead and 70 alive, nine of whom were on maintenance dialysis or transplanted, actuarial survivals being 84%, 72%, 62%, 61% and 54% at 5, 10, 15, 20 and 25 years for the group as a whole. Survival was be tter in the cohort 1976-86 (n=60) than in that from 1963-75 (n=50) (90, 81 and 76% vs. 78, 56 and 43% at 5, 10 and 15 years, p<0.001). Sepsis (12) and myocardial infarction (8) were the principal causes of death. Of living pa tients with renal function, 38% had normal urine and renal function, 11 wer e off all treatment (19%), 62% had persistent proteinuria and 18% had reduc ed but generally stable renal function, penal failure, in those patients wh o developed it, occurred during the first decade and none of 67 patients ac tually followed more than 10 years subsequently went into renal failure. in duction treatment was with prednisolone, combined with azathioprine in more severe forms of nephritis, and from the middle 1970s to 1986, 30 with meth ylprednisolone and in 12 cases plasma exchange. Seventeen other patients we re treated using oral cyclophosphamide during the 1960s. No patient receive d i.v. cyctophosphamide as induction therapy, although nine patients had th is form of treatment later, largely because of non-compliance. Serious comp lications of lupus and/or its treatment occurred in 49%: sepsis in 32, isch aemic heart disease in 20, thrombosis in one and avascular necrosis of bone in eight. In contrast, fracturing osteoporosis occurred in only three, and cataracts requiring surgery and diabetes mellitus in none. The very long-t erm outlook of lupus nephritis, especially its more severe forms, has impro ved, but that with current management strategies only a minority of patient s are able to stop treatment altogether, and the incidence of serious compl ications is high.